Affiliation:
1. Division of Nephrology, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu 42415, Republic of Korea
2. Quality Assessment Department, Health Insurance Review and Assessment Service, Wonju 26465, Republic of Korea
3. Healthcare Review and Assessment Committee, Health Insurance Review and Assessment Service, Wonju 26465, Republic of Korea
Abstract
This study aimed to evaluate the effect of statin solubility on the survival of patients undergoing hemodialysis (HD). This retrospective study used laboratory and clinical data from a national HD quality assessment program and claims data (n = 53,345). The use of statins was defined as prescription ≥30 days during 6 months of each HD quality assessment period. We divided the patients into three groups based on the use and solubility of statins: No group, patients without a prescription of statins (n = 37,944); Hydro group, patients with a prescription of hydrophilic statins (n = 2823); and Lipo group, patients with a prescription of lipophilic statins (n = 12,578). The 5-year survival rates in the No, Hydro, and Lipo groups were 69.6%, 67.9%, and 67.9%, respectively (p < 0.001 for the trend). Multivariable Cox regression analyses showed that the Lipo group had better patient survival than the No group. However, multivariable analyses did not show statistical significance between the Hydro and No or Lipo groups. In all subgroups based on sex, age, presence of diabetes mellitus, and heart disease, the Lipo group had better patient survival than the No group. We identified no significant association between hydrophilic and lipophilic statins and patient survival. However, patients taking lipophilic statins had a modest survival benefit compared with those who did not receive statins.
Funder
Ministry of Science, ICT, and Future Planning
Ministry of Education
Korean government
Reference38 articles.
1. Excess mortality among patients on dialysis: Comparison with the general population in Korea;Choi;Kidney Res. Clin. Pract.,2014
2. ESRD Registry Committee: Korean Society of Nephrology (2023, August 31). Factsheet: CKD in Korea. Available online: https://ksn.or.kr/bbs/index.php?page=2&code=Factsheet.
3. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease;Yao;Scand. J. Urol. Nephrol.,2004
4. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group (2013). KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. Suppl., 3, 259–305.
5. Clinical Pharmacology of Statins: An Update;Ferri;Curr. Atheroscler. Rep.,2020